+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
EMCURE

Emcure Pharmaceuticals Share Price

₹1,877.40 +8.8 (0.47%)
43.70% Gain from 52W Low

14 Oct, 2026 11:32 AM (IST)

Emcure Pharmaceuticals live price: ₹1,877.40. It opened at ₹1,855 vs previous close ₹1,869; intraday high/low: ₹1,888/₹1,831. The 50 & 200 DMA stand at ₹1,904.40/₹1,732.60.

Emcure Pharmaceuticals Performance

  • Today's Low
  • ₹1,831
  • Today's High
  • ₹1,888
  • 52 Week Low
  • ₹1,307
  • 52 Week High
  • ₹2,101
  • Open Price₹1,855
  • Previous Close₹1,869
  • Volume126,957
  • 50 DMA₹1,904.40
  • 100 DMA₹1,847.40
  • 200 DMA₹1,732.60

Emcure Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -5.13%
  • Over 3 Month + 4.69%
  • Over 6 Month + 15.15%
  • Over 1 Year + 36.98%

Smart Investing Starts Here Start SIP with Emcure Pharmaceuticals for Steady Growth!

Invest Now

Emcure Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 35.2
  • PEG Ratio
  • 1
  • Market Cap Cr
  • 35,616
  • P/B Ratio
  • 6.8
  • Average True Range
  • 57.7
  • EPS
  • 53.3
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -14.7
  • RSI
  • 41.84
  • MFI
  • 38.67

Latest Stock News Updates

Emcure Pharmaceuticals approves merger of two wholly-owned subsidiaries

The amalgamation aims to achieve entity rationalisation and operational efficiency within the group, the company said in a regulatory filing

Emcure Pharmaceuticals Ltd - 544210 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026

Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement

Proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries of the Company with Emcure Pharmaceuticals Limited - Holding Company, subject to requisite statutory and regulatory approvals.

Emcure Pharmaceuticals Financials

Emcure Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,877.40
+ 8.8 (0.47%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹1,911.60
  • 50 Day
  • ₹1,904.40
  • 100 Day
  • ₹1,847.40
  • 200 Day
  • ₹1,732.60

Resistance and Support

1865.57 Pivot Speed
  • R3 1,909.20
  • R2 1,893.70
  • R1 1,881.10
  • S1 1,853.00
  • S2 1,837.50
  • S3 1,824.90

Emcure Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-06 Quarterly Results
2026-05-05 Audited Results & Final Dividend
2026-02-04 Quarterly Results
2025-11-11 Quarterly Results
2025-08-07 Quarterly Results
Date Purpose Remarks
2026-09-04 FINAL Rs.3.60 per share(36%)Final Dividend
2025-08-14 FINAL Rs.3.00 per share(30%)Final Dividend
View Emcure Pharmaceuticals Dividend History Arrow

Emcure Pharmaceuticals Shareholding Pattern

77.83%
8.84%
6.87%
4.87%
1.59%

About Emcure Pharmaceuticals

Emcure Pharmaceuticals is engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. View More
  • NSE Symbol
  • EMCURE
  • BSE Symbol
  • 544210
  • Managing Director,Chief Executive Officer
  • SATISH RAMANLAL MEHTA
  • ISIN
  • INE168P01015

Similar Stocks to Emcure Pharmaceuticals

Emcure Pharmaceuticals FAQs

Emcure Pharmaceuticals share price is ₹1,877 As on 14 October, 2026 | 11:19

The Market Cap of Emcure Pharmaceuticals is ₹35616.3 Cr As on 14 October, 2026 | 11:19

The P/E ratio of Emcure Pharmaceuticals is 35.2 As on 14 October, 2026 | 11:19

The PB ratio of Emcure Pharmaceuticals is 6.8 As on 14 October, 2026 | 11:19

The 52 week High & Low of Emcure Pharmaceuticals is ₹2100.7/₹1306.5 respectively As on 14 October, 2026 | 11:19

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23